GlobeNewswire by notified

Verisk Welcomes Greg Hendrick to Its Board of Directors

Share

JERSEY CITY, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, today announced that Greg Hendrick has been appointed independent director of the company’s Board of Directors effective immediately. Hendrick brings more than three decades of extensive insurance and reinsurance leadership experience.

“We’re thrilled to welcome Greg to the Board,” Verisk president and CEO Lee Shavel said. “Greg’s deep understanding of the insurance industry and its changing market dynamics will serve Verisk well as we continue to innovate on behalf of our clients and extend our role as a trusted partner to the global insurance industry.”

Hendrick, 58, is CEO of Vantage Group, which provides specialty insurance, reinsurance and insurance-linked securities products. Before that, he served as CEO of AXA XL, the P&C and specialty risk division of AXA. He spent 25 years serving in numerous leadership roles at XL Group companies, including chief executive of reinsurance and chief executive of insurance. Hendrick began his career at AIG.  

Hendrick earned a Bachelor of Science in Mathematics from St. John’s University. He currently serves on the Board of Governors of St. John’s University and the Board of Overseers of the Greenberg School of Risk Management.

Bruce Hansen, chair of the Verisk Board of Directors, said, “We continue to add incredible talent and diverse perspectives to our Board. Greg’s profound industry and leadership experience will only accelerate the Board’s contributions to the company’s strategy and our commitment to delivering long-term shareholder value.”

About Verisk

Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, extreme events, ESG and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by Great Place to Work and fosters an inclusive culture where all team members feel they belong. For more, visit Verisk.com and the Verisk Newsroom.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

HiddenA line styled icon from Orion Icon Library.Eye